Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA

Panelists discuss how autologous stem cell transplant (ASCT) deferral should be approached cautiously with concrete medical reasons, as transplant continues to provide superior progression-free survival and potentially curative outcomes for a subset of patients.

Panelists discuss how maintenance therapy should be tailored based on risk profiles, with standard-risk patients receiving single-agent lenalidomide while high-risk patients may benefit from combination maintenance strategies to achieve more durable responses.

Panelists discuss how minimal residual disease (MRD) status can guide post-transplant treatment decisions, particularly for high-risk patients who don’t achieve MRD negativity and patients considering discontinuation of long-term maintenance therapy.

Panelists discuss how quadruplet regimens show improved efficacy over triplet regimens without significantly increased safety concerns, with anti-CD38 antibodies being well tolerated and NCCN guidelines now recommending 4-drug regimens for transplant-eligible patients.

Panelists discuss how treatment strategies differ between transplant-eligible and transplant-ineligible multiple myeloma patients, with transplant eligibility determined by functional status rather than age alone, and how quadruple therapy regimens are increasingly used for transplant-eligible patients to achieve deep, durable responses.

Panelists discuss how autologous stem cell transplant remains essential in frontline multiple myeloma management despite improved quadruple therapy outcomes, emphasizing that current evidence still supports transplantation for eligible patients rather than deferring it.

Medical experts offer their insights and closing remarks regarding patient feedback for MDS.

Medical experts discuss considerations and patient guidance for oral and IV HMAs.

Medical experts discuss innovations and future directions in treatments for higher-risk MDSMedical experts offer patient perspectives on advantages and disadvantages of using oral HMAs vs injectable HMAs.

Medical experts discuss innovations and future directions in treatments for higher-risk MDS.

Medical experts offer insights on the persistence and effectiveness of HMAs in patients with higher-risk MDS.

Medical experts discuss convenience and efficacy in higher-risk MDS regarding oral vs injectable HMAs.

Medical experts discuss the data gathered from the ASCERTAIN trial.

Medical experts offer insights on the COMMANDS trial findings.

Medical experts discuss risk-based approaches to choosing MDS therapies.

After a brief introduction, medical experts discuss advances in MDS classification and molecular understanding.